The global blood screening market was valued at USD 2.31 billion in 2018 and is anticipated to grow to USD 6.63 billion by 2032, reflecting a compound annual growth rate (CAGR) of 7.9% over the forecast period. In 2018, North America led the global market, accounting for 41.86% of the total share.

The blood screening market involves the testing of donated blood and plasma for infectious diseases, genetic disorders, and other health markers to ensure safety and accuracy before transfusion or further medical use. This market is driven by the growing need for early diagnosis, increasing prevalence of chronic and infectious diseases, and the expansion of blood donation and transfusion services globally. Technological advancements, such as nucleic acid testing (NAT), immunoassays, and automation in diagnostic laboratories, have significantly enhanced the efficiency and reliability of blood screening processes. As healthcare systems focus more on preventive care and patient safety, the Blood Screening Market continues to gain momentum. Despite some challenges such as high costs and limited infrastructure in low-resource regions, the ongoing demand for high-quality diagnostics sustains the long-term growth of the Blood Screening Market.

Continue reading for more details:

https://www.fortunebusinessinsights.com/blood-screening-market-102552

Market Segmentation

• By Technology: The Blood Screening Market is divided into immunoassays, nucleic acid testing (NAT), serological tests, and rapid diagnostic tests.

• By Application: Screening for infectious diseases, cancer biomarkers, genetic disorders, and anemia contribute diverse segments within the Blood Screening Market.

• By End‑User: Hospital labs, diagnostic centers, blood banks, and reference laboratories each capture distinct portions of the Blood Screening Market.

• By Sample Type: The Blood Screening Market includes whole blood, serum, plasma, and point-of-care sample formats.

List Of Key Companies Profiled:

• Bio-Rad Laboratories, Inc.

• Grifols, S.A.

• Hoffmann-La Roche

• Ortho Clinical Diagnostics

• BD

• DiaSorin S.p.A.

• Thermo Fisher Scientific Inc.

• Abbott

• QUOTIENT

• Other Players

Market Growth

• The Blood Screening Market has experienced strong upward momentum due to increasing demand for early disease detection and blood safety.

• Rising prevalence of infectious diseases and chronic conditions is driving rapid expansion of the Blood Screening Market.

• Technological innovations such as automated immunoassays, molecular diagnostics, and high-throughput screening are fueling the Blood Screening Market growth.

• Expansion in blood transfusion services and donor screening programs continues to propel the Blood Screening Market forward.

Restraining Factors

• High costs of advanced screening technologies and equipment are significant restraints on the Blood Screening Market.

• Regulatory complexities and varying approval timelines hinder product launches within the Blood Screening Market.

• Limited infrastructure in low- and middle-income countries restricts accessibility to blood screening solutions, impacting the Blood Screening Market.

• Concerns over data privacy and accuracy of rapid point-of-care tests pose challenges within the Blood Screening Market.

Regional Analysis

• North America: Dominates the Blood Screening Market due to advanced healthcare infrastructure and stringent safety regulations.

• Europe: Growth in the Blood Screening Market is driven by nationwide donor screening programs and adoption of molecular testing.

• Asia-Pacific: Witnessing rapid growth in the Blood Screening Market, powered by rising healthcare investment and increasing disease burden.

• Latin America & MEA: The Blood Screening Market is expanding steadily, though hampered by budget constraints and limited regulatory harmonization.

Contact us:

Fortune Business Insights™ Pvt.

Phone: USA: +1 833 909 2966 (Toll-Free),

United Kingdom: +44 808 502 0280 (Toll-Free)

APAC: +91 744 740 1245

Email: sales@fortunebusinessinsights.com